Disc Medicine (IRON) Change in Account Payables (2020 - 2026)
Disc Medicine (IRON) reported Change in Account Payables of $2.7 million for Q1 2026, up 314.64% year-over-year from $661049.5 in Q1 2025, and up 56.63% on a QoQ basis from $1.8 million in Q4 2025.
Disc Medicine (IRON) has 7 years of Change in Account Payables data on file, last reported at $2.7 million in Q1 2026.
- Quarterly Change in Account Payables rose 314.64% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.1 million (up 262.91% YoY) and the FY2025 annual result came in at $1.1 million, up 122.86% from the prior year.
- Change in Account Payables grew to $2.7 million in Q1 2026 per IRON's latest filing, from $1.8 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $4.4 million in Q4 2024 and bottomed at -$10.8 million in Q1 2023.
- The 5-year median for Change in Account Payables is -$321000.0 (2025), against an average of -$240294.1.
- Peak annual rise in Change in Account Payables reached 5463.51% in 2023, while the deepest fall reached 994.7% in 2023.
- Tracing IRON's Change in Account Payables over 5 years: stood at -$74000.0 in 2022, then surged by 5463.51% to $4.0 million in 2023, then increased by 10.73% to $4.4 million in 2024, then slumped by 60.18% to $1.8 million in 2025, then jumped by 56.63% to $2.7 million in 2026.
- Per Business Quant, the three latest IRON Change in Account Payables figures stand at $2.7 million (Q1 2026), $1.8 million (Q4 2025), and $918000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -3.26 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 35.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Disc Medicine | 2.76 Bn | 2.03 Bn | - | 2.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.74 Mn |
| Mar 31, 2026 | 2.74 Mn |
| Dec 31, 2025 | 1.75 Mn |
| Dec 31, 2025 | 1.75 Mn |
| Sep 30, 2025 | 918,000.00 |
| Sep 30, 2025 | 918,000.00 |
| Jun 30, 2025 | -321,000.00 |
| Jun 30, 2025 | -321,000.00 |
| Mar 31, 2025 | -1.28 Mn |
| Mar 31, 2025 | -1.28 Mn |
| Dec 31, 2024 | 4.40 Mn |
| Dec 31, 2024 | 4.40 Mn |
| Sep 30, 2024 | -1.05 Mn |
| Sep 30, 2024 | -1.05 Mn |
| Jun 30, 2024 | -669,000.00 |
| Jun 30, 2024 | -669,000.00 |
| Mar 31, 2024 | -7.36 Mn |
| Mar 31, 2024 | -7.36 Mn |
| Dec 31, 2023 | 3.97 Mn |
| Dec 31, 2023 | 3.97 Mn |
| Sep 30, 2023 | 3.77 Mn |
| Sep 30, 2023 | 3.77 Mn |
| Jun 30, 2023 | -726,000.00 |
| Jun 30, 2023 | -726,000.00 |
| Mar 31, 2023 | -10.75 Mn |
| Mar 31, 2023 | -10.75 Mn |
| Dec 31, 2022 | -74,000.00 |
| Dec 31, 2022 | -74,000.00 |
| Sep 30, 2022 | -403,000.00 |
| Sep 30, 2022 | -403,000.00 |
| Jun 30, 2022 | 1.99 Mn |
| Jun 30, 2022 | 1.99 Mn |
| Mar 31, 2022 | -982,000.00 |
| Mar 31, 2022 | -982,000.00 |
| Dec 31, 2021 | 1.77 Mn |
| Dec 31, 2021 | 1.77 Mn |
| Sep 30, 2021 | -501,000.00 |
| Sep 30, 2021 | -501,000.00 |
| Jun 30, 2021 | -2.13 Mn |
| Jun 30, 2021 | -2.13 Mn |
| Mar 31, 2021 | 2.17 Mn |
| Mar 31, 2021 | 2.17 Mn |
| Dec 31, 2020 | 3,653.00 |
| Dec 31, 2020 | 3,653.00 |
| Sep 30, 2020 | 39,489.00 |
| Sep 30, 2020 | 39,489.00 |
| Jun 30, 2020 | -1.66 Mn |
| Jun 30, 2020 | -1.66 Mn |
| Mar 31, 2020 | 715,000.00 |
| Mar 31, 2020 | 715,000.00 |